



31.01.2022

14:00 - 15:30 Management of local disease Channel 2

Moderation: E. Baldini¹, P. Hohenberger², ¹Boston/US, ²Mannheim/DE

14:00 - 14:15 The pathology of STS and GIST

M. Sbaraglia, Treviso/IT

14:15 - 14:30 The pathology of bone sarcomas

S. Wai Lam, Leiden/NL

14:30 - 14:45 The genetics of GIST

E. Wardelmann, Muenster/DE

14:45 - 15:00 Surgical margins in sarcomas and GIST

M. Smith, London/GB

15:00 - 15:15 Principles of radiation therapy in STS

A. Miah, London/GB

15:15 - 15:30 Live discussion

14:00 - 15:30 Paediatric / AYA sarcomas Channel 1

Moderation: J. Bovée¹, B. Hassan², M. Van De Sande¹, ¹Leiden/NL, ²Oxford/GB

14:00 - 14:30 Case presentation 1 and discussion

U. Dirksen, Essen/DE

14:30 - 15:00 Case presentation 2 and discussion

B. Kasper, Mannheim/DE

15:00 - 15:30 Case presentation 3 and discussion

K. Janeway, Boston/US

| | | |
|----------------------|---|------------------|
| 15:45 - 17:15 | GIST | Channel 1 |
| | Moderation: S. Bauer ¹ , J. Trent ² , E. Wardelmann ³ , ¹ Essen/DE, ² Miami/US, ³ Muenster/DE | |
| 15:45 - 16:15 | Case presentation 1 and discussion <u>A. Gronchi</u> , Milan/IT | |
| 16:15 - 16:45 | Case presentation 2 and discussion <u>S. Patel</u> , Houston/US | |
| 16:45 - 17:15 | Case presentation 3 and discussion <u>C. Raut</u> , Boston/US | |
| 15:45 - 17:15 | Management of advanced disease | Channel 2 |
| | Moderation: B. Kasper ¹ , R. Maki ² , ¹ Mannheim/DE, ² Philadelphia/US | |
| 15:45 - 16:00 | Principles of systemic therapy for sarcomas <u>M. Ahlström</u> , Lund/SE | |
| 16:00 - 16:15 | Targeted therapy for GIST <u>A. Le Cesne</u> , Villejuif/FR | |
| 16:15 - 16:30 | Immunotherapy for STS <u>C.M. Valverde Morales</u> , Barcelona/ES | |
| 16:30 - 16:45 | The value of WGS to search for therapeutic targets <u>R. Maestro</u> , Aviano/IT | |
| 16:45 - 17:00 | Local therapy for metastatic disease <u>A. Hayes</u> , London/GB | |
| 17:00 - 17:15 | Live discussion | |

01.02.2022

12:50 - 14:05 Deciphera Pharmaceuticals - Mutations and multi-modality treatment in patients with advanced GIST Channel 1

12:50 - 12:55 **Introduction**
H. Gelderblom, Leiden/NL

12:55 - 13:15 **Role of surgery in patients with advanced GIST**
A. Gronchi, Milan/IT

13:15 - 13:35 **GIST: Do mutations matter, and when?**
C. Serrano, Barcelona/ES

13:35 - 13:55 **Advanced GIST: Treatment or management?**
A. Le Cesne, Villejuif/FR

13:55 - 14:05 **Live Q&A and discussion**

14:15 - 14:35 ESMO Sarcoma & GIST 2022 Opening Channel 1
Moderation: J. Bovée¹, R. Jones², ¹Leiden/NL, ²London/GB

14:15 - 14:17 **ESMO Sarcoma & GIST 2022 Welcome**
J. Bovée, Leiden/NL

14:17 - 14:22 **ESMO Sarcoma & GIST 2022 Welcome**
J. Bovée¹, R. Jones², ¹Leiden/NL, ²London/GB

14:22 - 14:37 **Future perspectives and international collaborations in sarcomas**
J.-Y. Blay, Lyon/FR

14:45 - 16:15 GIST Channel 2
Moderation: S. George¹, A. Gronchi², ¹Boston/US, ²Milan/IT

- 14:45 - 15:00 **Pathology and molecular assessment of GIST: Implications for risk stratification**
J.A. Fletcher, Boston/US
- 15:00 - 15:15 **Improvement on local treatment: Use of image guided surgery**
Y. Schrage, Leiden/NL
- 15:15 - 15:30 **Update on medical therapy**
J. Trent, Miami/US
- 15:30 - 15:45 **Preclinical leads for novel therapeutic approaches**
S. Bauer, Essen/DE
- 15:45 - 16:00 **How to implement liquid biopsies in clinical trials**
C. Serrano, Barcelona/ES
- 16:00 - 16:15 **Live discussion**

14:45 - 16:15 STS 1 Channel 1
Moderation: J. Bovée¹, R. Jones², ¹Leiden/NL, ²London/GB

- 14:45 - 15:00 **Update on STS pathology: WHO, WGS, ICCR and more....**
C. Fletcher, Boston/US
- 15:00 - 15:15 **Is doxorubicin still the standard 1st line therapy for all sarcoma subtypes?**
P. Reichardt, Berlin/DE
- 15:15 - 15:30 **Ultrarare STS: How do we make progress?**
A.M. Frezza, Milan/IT
- 15:30 - 15:45 **Clinical trials for rare STS: How to learn the most from it**
A. Digklia, Lausanne/CH
- 15:45 - 16:00 **How to approach the surgical margin across STS subtypes**
P. Rutkowski, Warsaw/PL
- 16:00 - 16:15 **Live discussion**

16:30 - 18:00 STS 2 **Channel 1**
Moderation: A.M. Frezza¹, A. Hayes², ¹Milan/IT, ²London/GB

- 16:30 - 16:45 **The requirements of good surgery for STS, today**
S. Bonvalot, Paris/FR
- 16:45 - 17:00 **On the use of neoadjuvant chemotherapy: Pro’s**
A. Gronchi, Milan/IT
- 17:00 - 17:15 **On the use of neoadjuvant chemotherapy: Con’s**
A. Le Cesne, Villejuif/FR
- 17:15 - 17:30 **The management of residual disease after TKIs in GIST**
C. Swallow, Toronto/CA
- 17:30 - 17:45 **Radiotherapy: Can we do better with less?**
R.L. Haas, Amsterdam/NL
- 17:45 - 18:00 **Live discussion**

16:30 - 18:00 Bone tumours **Channel 2**
Moderation: S. Bielack¹, S. Strauss², ¹Stuttgart/DE, ²London/GB

- 16:30 - 16:45 **Bone sarcoma differential diagnosis: Methylation array versus morphology**
D. Baumhoer, Basel/CH
- 16:45 - 17:00 **Ultrarare bone cancers: How do we make progress?**
E. Palmerini, Bologna/IT
- 17:00 - 17:15 **Update on chordoma**
S. Stacchiotti, Milan/IT
- 17:15 - 17:30 **Proton therapy for chordoma and chondrosarcoma**
B. Timmermann, Essen/DE
- 17:30 - 17:45 **The risks versus benefits of denosumab for GCTB**
H. Gelderblom, Leiden/NL
- 17:45 - 18:00 **Live discussion**

02.02.2022

12:30 - 14:00 Update on clinical research in sarcoma field **Channel 1**
Moderation: R. Maki¹, A. Wagner², ¹Philadelphia/US, ²Boston/US

12:30 - 12:45 **Radiomics for sarcomas**
M. Blackledge, London/GB

12:45 - 13:00 **Update on novel statistical designs for rare cancer trials: What have we learned so far?**
B. Hassan, Oxford/GB

13:00 - 13:15 **What level of evidence do we need for drug approval in rare cancers?**
P.G. Casali, Milan/IT

13:15 - 13:30 **Lessons from the NET-SARC consortium**
M. Brahmi, Lyon/FR

13:30 - 13:45 **Proteomics in sarcomas: How to identify new biomarkers?**
P. Huang, London/GB

13:45 - 14:00 **Live discussion**

| | | |
|----------------------|---|------------------|
| 13:00 - 14:00 | Celebrating excellence in sarcoma treatment and care - the role of sarcoma centers of excellence | Channel 2 |
| | Moderation: G. Van Oortmerssen, Naarden/NL | |
| 13:00 - 13:02 | Introduction <u>G. Van Oortmerssen</u> , Naarden/NL | |
| 13:02 - 13:12 | The role of expert care: A question of outcome and prognosis? <u>S. Bickley</u> , London/GB | |
| 13:12 - 13:22 | A question of concept: Centers vs. networks <u>R. Wilson</u> ¹ , <u>D. Reinke</u> ² , ¹ London/GB, ² Ann Arbor/US | |
| 13:22 - 13:40 | A reality check: Challenges for excellence in sarcoma management <u>M. Wartenberg</u> ¹ , <u>V. Gupta</u> ² , ¹ Wölfersheim/DE, ² Mumbai/IN | |
| 13:40 - 13:50 | A wish for the future in sarcoma management &#38; care <u>O. Gonzato</u> , Udine/IT | |
| 13:50 - 14:00 | Closing and discussion <u>G. Van Oortmerssen</u> , Naarden/NL | |
| 14:15 - 15:30 | Immunotherapy in sarcomas | Channel 1 |
| | Moderation: J.-Y. Blay ¹ , P. Reichardt ² , ¹ Lyon/FR, ² Berlin/DE | |
| 14:15 - 14:30 | Search for predictive biomarkers: TMB, MMR and PDL1 <u>W.D. Tap</u> , New York/US | |
| 14:30 - 14:45 | Search for predictive biomarkers: Sarcoma immunoscore <u>J. Martin Broto</u> , Seville/ES | |
| 14:45 - 15:00 | Immunotherapy for sarcomas: What have we learned so far? <u>R. Maki</u> , Philadelphia/US | |
| 15:00 - 15:15 | Immunotherapy for sarcomas: Combination strategies <u>A. Napolitano</u> , London/GB | |
| 15:15 - 15:30 | Live discussion | |

14:15 - 15:30 Gynaecological and visceral sarcomas Channel 2
Moderation: R.L. Haas¹, C. Swallow², ¹Amsterdam/NL, ²Toronto/CA

14:15 - 14:30 **What's new in WHO for gynaecological and visceral sarcomas**
A.P. Dei Tos, Padova/IT

14:30 - 14:45 **Gynaecological and visceral sarcomas: Treat the same as other STS? RT view**
E. Baldini, Boston/US

14:45 - 15:00 **Gynaecological and visceral sarcomas: Treat the same as other STS?**
S. George, Boston/US

15:00 - 15:15 **Gynaecological and Visceral sarcoma: Treat the same as other STS? Surgical view**
P. Hohenberger, Mannheim/DE

15:15 - 15:30 **Live discussion**

15:45 - 17:15 Novel therapeutic approaches Channel 1
Moderation: P.G. Casali¹, W.D. Tap², ¹Milan/IT, ²New York/US

15:45 - 16:00 **Brachyury vaccination strategies for chordoma**
A. Wagner, Boston/US

16:00 - 16:15 **CAR-T cell / NY-ESO1 for synovial sarcoma**
G. Demetri, Boston/US

16:15 - 16:30 **WGS based tumour agnostic therapy: Where do we stand?**
A. Dufresne, Lyon/FR

16:30 - 16:45 **Drug repurposing and biomarker discovery using AI in sarcoma care**
D. Van Ijzendoorn, Stanford/US

16:45 - 17:00 **Individualised therapy for STS: On the use of an app**
M. Van De Sande, Leiden/NL

17:00 - 17:15 **Live discussion**

| | | |
|----------------------|---|------------------|
| 15:45 - 17:15 | Paediatric / AYA sarcomas | Channel 2 |
| | Moderation: A.P. Dei Tos ¹ , M. Ahlstrom ² , ¹ Padova/IT, ² Lund/SE | |
| 15:45 - 16:00 | Round cell sarcomas: Should we split or should we lump? <u>S. Strauss</u> , London/GB | |
| 16:00 - 16:15 | Impact of age on patient quality of life <u>W. Van Der Graaf</u> , Amsterdam/NL | |
| 16:15 - 16:30 | Impact of age on radiotherapy <u>A. Miah</u> , London/GB | |
| 16:30 - 16:45 | Osteosarcoma: Where do we go from here? <u>S. Bielack</u> , Stuttgart/DE | |
| 16:45 - 17:00 | Paediatric GIST: What makes it so different? <u>L. Helman</u> , Dallas/US | |
| 17:00 - 17:15 | Live discussion | |
| 17:20 - 17:25 | Closing & take home messages | Channel 1 |
| | Moderation: J. Bovée ¹ , R. Jones ² , ¹ Leiden/NL, ² London/GB | |